02.02.22
Johnson & Johnson
4Q Revenues: $24.8 billion (+10%)
4Q Earnings: $4.7 billion (+173%)
FY Revenues: $93.8 billion (+14%)
FY Earnings: $20.9 billion (+42%)
Comments: Pharmaceutical sales were $52.1 billion, up 14% for the year, driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), for the treatment of a number of immune- mediated inflammatory diseases, TREMFYA (guselkumab), for the treatment of moderate to severe plaque psoriasis, and active psoriatic arthritis, ERLEADA (apalutamide), for the treatment of prostate cancer, and INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia. Also contributing to growth were sales of the Janssen COVID-19 Vaccine (Ad26.COV2.S), which were $1.6 billion in the quarter and $2.4 billion for the year. This growth was partially offset by declines in sales of REMICADE (infliximab), a treatment of a number of immune- mediated inflammatory diseases. Sales were down 15% in the quarter to $764 million and down 15% for the year to $3.2 billion.
4Q Revenues: $24.8 billion (+10%)
4Q Earnings: $4.7 billion (+173%)
FY Revenues: $93.8 billion (+14%)
FY Earnings: $20.9 billion (+42%)
Comments: Pharmaceutical sales were $52.1 billion, up 14% for the year, driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), for the treatment of a number of immune- mediated inflammatory diseases, TREMFYA (guselkumab), for the treatment of moderate to severe plaque psoriasis, and active psoriatic arthritis, ERLEADA (apalutamide), for the treatment of prostate cancer, and INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia. Also contributing to growth were sales of the Janssen COVID-19 Vaccine (Ad26.COV2.S), which were $1.6 billion in the quarter and $2.4 billion for the year. This growth was partially offset by declines in sales of REMICADE (infliximab), a treatment of a number of immune- mediated inflammatory diseases. Sales were down 15% in the quarter to $764 million and down 15% for the year to $3.2 billion.